Figure Legends
Figure 1. A–E, Computed tomography (CT) scans and their date of examination.
A, Original tumor site. B, Metastasis to the peritoneal lymph node. C, Relapsed site (right kidney).D, CT findings before vaccination (no tumor). E, The latest CT findings (no tumor). Arrows indicate the location of the tumors. F, Immune response for vaccinated peptides. Arrows indicate the day of vaccination. “20XX” is the year of the first disease onset. G, Statistical analysis with the 2-fold Wilcoxon test.
Table 1: Abbreviation; VAC: vincristine, actinomycin D, cyclophosphamide chemotherapy, ICE: Ifosphamide, Carboplatin, Etoposide chemotherapy, IMRT: Intensity modulated radiation therapy, DXR: doxorubicin, MTX: methotrexate, IFO: ifosphamide, CDDP: cisplatinum, VDC: vincristine, doxorubicin, cyclophosphamide chemotherapy, IE: ifosphamide, etoposide chemotherapy, DD4A: d-actinomycin, doxorubicin, vincristine chemotherapy, PTK: Protein tyrosine kinases, TMZ: temozolomide, SD: stable disease, PD: progressive disease, OS: overall survival
Supplemental table 1: a: A3family, HLA-A3, A11, A31, and A33
Abbreviation: HLA, human leukocyte antgen ; TAA, tumor associated antigen
Supplemental table 2: Bold number indicated the selected peptide for vaccination